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Introduction
The activity of DNA-dependent protein kinase (DNA-PK) is essen-
tial to the repair of DNA double-strand breaks (DNA-DSBs) via 
canonical nonhomologous end joining (NHEJ) (1, 2). This repair 
mechanism involves recruitment of the DNA-PK holoenzyme 
to DNA-DSBs by two Ku70 and Ku80 heterodimeric subunits, 
which tethers the free DNA duplex strands together (3). A series 
of regulatory phosphorylation events, orchestrated by the serine/
threonine protein kinase activity of the DNA-PK catalytic subunit 
(DNA-PKcs), restricts processing of the DNA (4), promotes activa-
tion of additional repair proteins required for DNA ligation (5, 6), 
and regulates the subsequent dissociation of DNA-PK from the Ku 
heterodimer (7). In contrast to the higher-fidelity repair of DNA-
DSBs by homologous recombination, NHEJ occurs throughout the 
cell cycle and can function as a more rapid repair process to limit 
chromosomal translocations (8, 9).
Targeting of DNA-PK catalytic activity has been proposed as a 
strategy to augment the antitumor activity of clinically used thera-
pies that result in DNA-DSBs, such as treatment with topoisomerase 
II inhibitors (e.g., doxorubicin or etoposide) or radiotherapy (10, 11). 
This rationale is also predicated on the fact that DNA-PK activation 
and gene expression have been shown to be elevated in a number 
of tumor types, including chronic lymphocytic leukemia, ovarian 
cancer, and hepatocellular cancer (HCC), and correlate with a poor 
outcome to standard therapies (12–14). A potential concern with 
this approach, however, is whether inhibition of DNA-PK catalytic 
activity will exacerbate the normal tissue toxicity of DNA-damaging 
agents to a level that necessitates a reduction in the standard-of-
care treatment, thereby limiting the potential of the combination 
to afford an increased therapeutic outcome. This apprehension is 
founded in the knowledge that all nucleated cells contain the pro-
teins required for NHEJ and that extreme sensitivity has been pre-
viously encountered (including fatalities) when leukemic patients 
with genetic deficiencies in the core NHEJ component DNA ligase 
IV have been treated with either myeloablative preconditioning ther-
apy or prophylactic cranial irradiation (15, 16). Presently, it remains 
unclear whether transient pharmacological inhibition of DNA-PKcs 
can be harnessed to provide an increased therapeutic index.
Potentiating radiotherapy and chemotherapy by inhibiting DNA damage repair is proposed as a therapeutic strategy to 
improve outcomes for patients with solid tumors. However, this approach risks enhancing normal tissue toxicity as much as 
tumor toxicity, thereby limiting its translational impact. Using NU5455, a newly identified highly selective oral inhibitor of 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activity, we found that it was indeed possible to preferentially 
augment the effect of targeted radiotherapy on human orthotopic lung tumors without influencing acute DNA damage or a 
late radiation-induced toxicity (fibrosis) to normal mouse lung. Furthermore, while NU5455 administration increased both 
the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor, it enhanced the activity of doxorubicin 
released locally in liver tumor xenografts without inducing any adverse effect. This strategy is particularly relevant to 
hepatocellular cancer, which is treated clinically with localized drug-eluting beads and for which DNA-PKcs activity is reported 
to confer resistance to treatment. We conclude that transient pharmacological inhibition of DNA-PKcs activity is effective and 
tolerable when combined with localized DNA-damaging therapies and thus has promising clinical potential.
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ation treatment in the presence and absence of NU5455 (5 μM). 
Treatment with NU5455 led to a significant increase in the num-
ber of colocalized γH2AX and 53BP1 foci observed at 5 hours after 
irradiation (Supplemental Figure 4).
Collectively these data indicate NU5455 to be a highly selec-
tive inhibitor of DNA-PKcs that is active in cells and that can per-
turb DNA-DSB repair by NHEJ.
NU5455 is an effective radiosensitizer in vitro. We examined the 
ability of NU5455 to enhance a 2-Gy dose of IR in comparison with 
treatment with inhibitors of other DNA repair enzymes — namely 
KU55933, which inhibits ATM serine/threonine kinase (a DNA-
DSB repair checkpoint that activates a range of proteins including 
p53 and Chk2) (20); rucaparib, which inhibits poly(ADP-ribose) 
polymerase (PARP; involved in DNA single-strand repair) (21); and 
VE-821, which inhibits ATR serine/threonine kinase (involved in 
DNA single-strand break repair and activation of Chk1) (22). Each 
inhibitor was studied in MCF7 breast tumor cells over a range that 
included concentrations previously shown to be pharmacolog-
ically active (10 μM KU55933 [ATM], 0.4 μM rucaparib [PARP], 
and 1 μM VE-821 [ATR]) (20–22). While the clonogenic cell killing 
induced by treatment with 2 Gy IR was further enhanced by treat-
ment with the relevant concentrations of an ATM or ATR inhib-
itor (KU55933, 2.3-fold at 10 μM [P = 0.04]; VE-821, 1.6-fold at 
1 μM [P = 0.02]), the potential radio-enhancement observed with 
the PARP inhibitor did not quite reach statistical significance (1.4-
fold at 1 μM [P = 0.08]). In comparison, combination therapy with 
NU5455 had a significantly more profound effect, with NU5455 
monotherapy potentiating the effect of 2 Gy IR 11.5-fold at 1 μM 
and 38-fold at 3 μM (both P = 0.0001 respectively; Figure 2A).
The formation of DNA-DSBs can be induced either through 
direct radiation damage or from stalled DNA replication forks 
that can persist into S phase (23) and that may potentially be 
more evident in tumor cells with a compromised G1/S check-
point. While the repair of DNA-DSBs by NHEJ is suggested to 
occur throughout the cell cycle (24), this may also be influenced 
by replication, representing the major repair pathway for radia-
tion-induced DNA-DSBs during G1 (25). To examine the influence 
of cellular proliferation on DNA-DSB repair following irradiation 
and NU5455 treatment, the clonogenic survival of MCF7 tumor 
cells was measured either in cells undergoing normal exponen-
tial growth or in those that had been allowed to reach confluence 
before treatment and in which an increased G0/G1 fraction (from 
29.1% ± 4.9% to 77.8% ± 2.9%) and diminished S phase fraction 
(from 42.0% ± 3.6% to 6.6% ± 2.3%) were observed (n = 4, mean 
± SEM; Supplemental Figure 5A). The irradiation of confluent 
MCF7 cells did not appear to markedly influence the repair of 
potentially lethal damage (26), as their intrinsic radiosensitivity 
was not significantly different from that of proliferating cells at 
any dose of IR examined (Figure 2B; P = 0.13–0.92). In contrast, 
proliferating MCF7 cells were more sensitive than confluent cells 
to treatment with the combination of NU5455 and IR, at 0.4 Gy 
(P = 0.009), 0.8 Gy (P = 0.00002), and 1.6 Gy (P = 0.0003) (Fig-
ure 2B). Experiments were also conducted in nontumorigenic 
MCF10A normal breast epithelial cells (27), using confluence 
conditions that increased the G0/G1 fraction from 62% ± 7.9% to 
95% ± 1.6% (n = 4, mean ± SEM; Supplemental Figure 5B). Con-
fluent MCF10A cells were found to be more intrinsically radio-
We report the identification of NU5455, a novel highly selec-
tive orally bioavailable inhibitor of DNA-PKcs activity. NU5455 
was used to evaluate pharmacological DNA-PKcs inhibition in 
combination with ionizing radiation (IR) or topoisomerase II 
inhibitors, by examining the responses of both tumor and nor-
mal tissues to treatment. Encouragingly, the data indicate that 
selective and transient DNA-PKcs inhibition in vivo can favorably 
augment an IR antitumor response without significantly affecting 
the resolution of acute DNA damage in normal tissues or exacer-
bating a late radiation-induced toxicity. In addition, we highlight 
the potential of using an oral DNA-PKcs inhibitor to enhance the 
antitumor activity of localized doxorubicin-eluting beads without 
an adverse effect on the host: an approach that has translational 
potential for the treatment of HCC.
Results
NU5455 selectively inhibits DNA-PK activity and DNA-DSB repair. 
NU5455 (Figure 1A and Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI127483DS1) was tested at 1 μM against 345 wild-type and 56 
mutant kinases (Life Technologies SelectScreen), and found to 
be a highly selective ATP-competitive kinase inhibitor: the kinase 
activity of DNA-PKcs, Vps34, and PI3Kδ was inhibited by 98%, 
86%, and 57%, respectively, but little inhibitory activity was 
demonstrated against the remaining 398 kinases, with less than 
10% inhibition in the majority and 20%–29% inhibition evident in 
only 2 others (Supplemental Table 1). IC50 determinations against 
each of the PI3K family members further verified that NU5455 
was a potent inhibitor of DNA-PKcs activity (IC50 of 8.2 ± 2 nM; 
Figure 1A and Supplemental Table 2), with selectivity versus Vps34 
(8.7-fold), PI3Kδ (33.7-fold), and ATM and ATR (both >1200-fold). 
Importantly, NU5455 demonstrated a 228-fold selectivity mar-
gin for DNA-PKcs kinase activity versus that of PI3Kα, activity 
against the latter being evident with a number of earlier DNA-
PKcs inhibitors (e.g., KU60648; ref. 17), which is preferably avoid-
ed, given that PI3Kα signaling has a key cardioprotective role (18). 
This activity and selectivity were also evident at a cellular level. 
NU5455 inhibited radiation-induced activation of DNA-PK with 
an IC50 of 168 nM (Figure 1B) but did not inhibit IGF-stimulated 
activation of AKT in MCF7 cells even at 10 μM (Figure 1C), which 
is mediated by IGF-1R activation of the p85 regulatory subunit of 
PI3K (19). In contrast, while our widely used prototype DNA-PKcs 
inhibitor NU7441 demonstrated similar activity against DNA-PK 
activation in MCF7 cells (IC50 of 405 nM), it also inhibited an IGF/
PI3K-stimulated signaling response by 40% ± 7% at 1 μM (Figure 
1, B and C, and Supplemental Figure 2).
To examine the mechanistic consequences of NU5455 treat-
ment for DNA-DSB repair, HEK293T cells were transfected with 
a dual BFP- and GFP-containing reporter construct that enabled 
quantification of the repair of DNA-DSBs generated following 
treatment with either AfeI or ScaI restriction endonucleases. 
NU5455 (1 μM) was found to inhibit the repair of DNA-DSBs 
induced by treatment with either enzyme within a 24-hour period 
(Figure 1D and Supplemental Figure 3). In addition, phosphory-
lation of histone H2AX (γH2AX) and the formation of 53BP1 foci 
were quantified in Calu-6 and A549 human lung cancer cells as 
early biomarkers of DNA-DSB formation, following 10 Gy of radi-
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at all IR doses). Collectively, these data suggest that the combina-
tion of IR and NU5455 can induce more pronounced cell killing 
in proliferating, as opposed to confluent, tumor cells, but that the 
response to combination treatment, and influence of cell cycle 
phase, may be cell type–dependent.
resistant than proliferating cells at 1.6 and 2.5 Gy (P = 0.03 and 
0.01, respectively; Figure 2C). However, while NU5455 treatment 
enhanced the activity of IR in MCF10A cells, the clonogenic sur-
vival of confluent and proliferating MCF10A cells following com-
bination treatment did not differ significantly (Figure 2C; P > 0.2 
Figure 1. NU5455 is a selective inhibitor of DNA-PKcs activity. (A) Chemical structure of the DNA-PK inhibitor NU5455 (molecular weight = 595.71). The in 
vitro potency of NU5455 against DNA-PK and other kinases was assessed by SelectScreen Profiling (Life Technologies). Data depicted graphically represent 
the cell-free NU5455 IC50 values for PI3K family members (mean ± SEM, n = 4–7) and inhibitory activity of 1 μM NU5455 when tested against a panel of 345 
wild-type kinases. (B and C) Changes in phospho–DNA-PK Ser2056 and phospho–AKT Ser473 30 minutes after treatment with 10 Gy IR or 50 ng/mL IGF-1, 
respectively, in MCF7 cells pretreated with vehicle, NU5455, or NU7441 for 1 hour. Percentage activity was determined relative to total DNA-PK or AKT using 
densitometry. (D) Plasmid repair assay enabling quantification of NHEJ-mediated DSB repair in HEK293T cells by measurement of the relative proportions 
of BFP and GFP. Cells were transfected with intact or linearized (AfeI or ScaI restriction endonuclease–treated) plasmid DNA and treated with NU5455 for 
24 hours. With the exception of the broad kinase panel screen, all data represent the mean ± SEM from 4–7 (A) and 3 (B–D) independent experiments. 
Statistical significance was assessed using unpaired t tests (B and C) and 2-way ANOVA (D). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 2. NU5455 is an effective radiosensitizer in vitro. (A) Clonogenic survival of MCF7 cells pretreated with NU5455, the ATM inhibitor KU55933, the 
PARP inhibitor rucaparib, or the ATR inhibitor VE-821 for 1 hour before IR (2 Gy). Clonogenic assays involved continued incubation with compounds prior 
to reseeding of cells into drug-free media 24 hours after irradiation. SER, sensitization enhancement ratio. (B and C) MCF7 (B) and MCF10A (C) clonogenic 
survival under confluent or exponentially growing conditions. Cells were treated with vehicle or NU5455 (1 μM) for 1 hour before irradiation and reseeding 
24 hours after irradiation. SER80 indicates the SER between radiation doses with and without NU5455 that induced an 80% inhibition of clonogenic cell 
survival (LD80). (D) Clonogenic survival of MCF7 cells pretreated with NU5455 (1 μM) for 1 hour before irradiation, and for a further 1, 2, 4, 6, or 24 hours after 
irradiation before incubation in drug-free media prior to reseeding at 24 hours. (E) Integrated total nuclear fluorescence of γH2AX foci in MCF7 cells pre-
treated with NU5455 (1 μM) for 1 hour and fixed 0–24 hours after irradiation (2.5 Gy). At least 50 cells were analyzed per treatment group. (F) LD80 values 
from clonogenic survival assays of cell lines treated with vehicle or NU5455 (1 μM) for 1 hour before, and 24 hours after, irradiation. Fold potentiation is 
shown above each cell line. All graphs (A–F) represent the mean ± SEM from at least 3 independent experiments, with the exception of graph E, which is 
a single representative of 2 independent experiments (see also Supplemental Figure 6). Statistical significance was assessed using unpaired t tests, with 
the exception of graph E, for which Mann-Whitney U tests were used. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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of 3.3 Gy radiation produced a relatively marginal inhibition of 
Calu-6 tumor growth, the concurrent administration of NU5455 
enhanced the antitumor activity significantly to induce a cytostat-
ic response for 6 days following treatment (mean tumor volume = 
104 mm3 at day 0 vs. 102 mm3 at day 6) (Figure 3A). As antibodies 
against human phospho–DNA-PK (Ser2056) do not cross-react 
with the complementary phosphorylation site in murine DNA-PK 
(Ser2053) (28), further ex vivo comparisons between mouse skin 
and human tumor tissues were based on quantification of γH2AX, 
reflecting DNA-DSBs. A histological analysis of Calu-6 subcuta-
neous tumors indicated that the number of radiation-induced 
γH2AX foci remaining 5 hours after irradiation was 3.0-fold great-
er (P = 0.01) with concomitant NU5455 treatment (Figure 3B and 
Supplemental Figure 11A). In contrast, 5 hours after irradiation, 
the number of radiation-induced γH2AX foci in the skin imme-
diately surrounding the tumor was augmented only 1.6-fold with 
NU5455 treatment (Figure 3C and Supplemental Figure 11A), a 
change that did not reach statistical significance (P = 0.09). These 
observations are likely to reflect a difference in the rate of repair 
of DNA-DSBs in the presence of NU5455, with radiation-induced 
DNA-DSBs being potentially less efficiently resolved in Calu-6 
tumors versus skin. In addition, since Calu-6 tumor cells will have 
a greater proliferation rate than normal mouse skin, their replica-
tion past unrepaired DNA-DSBs could conceivably also contrib-
ute to additional γH2AX foci that are retained in the presence of 
NU5455. A pharmacokinetic analysis of NU5455 following admin-
istration of a 30-mg/kg oral dose of NU5455 to Calu-6 tumor–
bearing mice indicated that the NU5455 concentrations in plasma, 
lung, tumor, or the surrounding skin were maintained at approxi-
mately 1 μM (i.e., 0.6 μg/mL or μg/g tissue) or above for a period of 
3 hours (Figure 3D). Notably, the concentration of NU5455 in the 
tumor compartment was similar to that in the adjacent skin and 
did not exceed the latter at any time (Figure 3D).
When NU5455 was combined with a 10-Gy dose of radiation, 
regression of Calu-6 tumors was induced (Figure 3E), with 3 of 6 
mice having no evidence of tumor at the end of the experiment 
(day 38). This enhanced antitumor response was achieved without 
any adverse effect or impact on body weight (Figure 3F). With this 
increased radiation dose, a greater number of γH2AX foci were 
evident in Calu-6 tumors 24 hours after treatment, which was ele-
vated further by concurrent NU5455 administration (Figure 3G 
and Supplemental Figure 11B). The magnitude of 53BP1 staining 
was also increased when NU5455 was combined with 10 Gy of 
radiation, indicative of a greater engagement of repair by NHEJ 
(Figure 3G and Supplemental Figure 11B). NU5455 also enhanced 
the antitumor activity of a 10-Gy radiation treatment in the A549 
lung tumor model (Figure 3H), which was similarly accompanied 
by an increase in the number of γH2AX foci and 53BP1 staining 
(Figure 3I and Supplemental Figure 11C). That the magnitude of 
radio-enhancement by NU5455 was less than in the Calu-6 model 
may reflect a cell-intrinsic difference between the 2 tumors that 
was also evident in vitro (Figure 2F).
NU5455 augments external beam radiotherapy in orthotopic lung 
tumor xenografts but does not significantly enhance radiation-induced 
damage to normal lung. Luciferase-expressing Calu-6 cells were 
implanted orthotopically into the lungs of CD-1 nude mice and the 
effect of treatment with 10 Gy thoracic radiation with or without 
We also explored the effect of NU5455 (1 μM) treatment dura-
tion on the sensitivity of MCF7 cells to IR. The ability of NU5455 to 
enhance radiation-induced clonogenic survival was highly depen-
dent on incubation time; LD80 values indicated 1 hour of NU5455 
treatment to produce only a marginal effect that did not reach 
statistical significance (1.2-fold, P = 0.09), 4- to 6-hour treatment 
to enhance the radiation response significantly (1.5- to 1.7-fold, 
P < 0.002), and 24-hour treatment to elicit further radio-enhance-
ment (2.4-fold, P <0.0001) (Figure 2D). An analysis of γH2AX foci 
following 2.5 Gy irradiation in MCF7 cells revealed that incubation 
with NU5455 enhanced the number of foci formed within 1 hour 
of irradiation (Figure 2E and Supplemental Figure 6). While some 
resolution of the γH2AX foci was evident in cells either without 
or with continuous NU5455 treatment, the number of foci in the 
NU5455-treated cells remained elevated even at 24 hours (Figure 
2E and Supplemental Figure 6).
The radiosensitizing effect of NU5455 treatment was further 
examined in different cell lines. This included HCT116 colorectal 
carcinoma DNAPK–/– cells, in which the effect of radiation was 
not augmented by treatment with NU5455 (1 μM), in contrast to 
isogenic HCT116 parental cells, in which a significant radiosensi-
tizing effect was observed (Figure 2F and Supplemental Figure 7). 
Similarly, concomitant NU5455 (5 μM) treatment did not alter the 
response of human chronic myeloid leukemia HAP-1 DNA-PK–
null cells to IR, but markedly increased the clonogenic cell-killing 
effect of 1–4 Gy IR in HAP-1 cells that express 1 copy of PRKDC 
(Supplemental Figure 8). These data are consistent with the radio-
sensitization effect of NU5455 being attributable to the inhibition 
of DNA-PKcs activity.
NU5455 treatment (1 μM, 24 hours) was also examined in 
cells representative of lung (A549, Calu-6) and colorectal cancer 
(HCT116, LoVo), osteosarcoma (SJSA-1), glioblastoma (U251), 
and HCC (Hep3B, HepG2, Huh7). While the tumor cell lines 
selected exhibited different intrinsic radiosensitivities and had 
differences in TP53 status (wild-type, mutant nonfunctional, and 
deleted; Supplemental Table 3), NU5455 enhanced the effect of IR 
significantly in all DNA-PK–expressing cells with the exception of 
LoVo, SER80 values (the sensitizing enhancement ratio 80, which 
is the ratio between radiation doses with and without NU5455 that 
induced an 80% inhibition of clonogenic cell survival) ranging 
from 1.5- to 5.0-fold (median 2.3-fold; Figure 2F and Supplemen-
tal Figure 7). A comparable level of radio-potentiation was also 
observed in 3 human noncancer cell lines (1.5- to 2.3-fold SER80) 
(Figure 2F and Supplemental Figure 9). Similarly, NU5455 was 
found to enhance the effect of IR in both mouse tumor and normal 
fibroblast cell lines (1.5- to 2.0-fold SER80) (Figure 2F and Supple-
mental Figure 10). These data verify that NU5455 can significant-
ly increase the radiosensitivity of DNA-PK–expressing tumor and 
normal/fibroblast cells of both human and murine origin in vitro.
NU5455 augments external beam radiotherapy in subcutaneous 
lung tumor xenografts. To determine whether the radio-enhanc-
ing activity of NU5455 could also be observed in vivo, Calu-6 and 
A549 human non–small cell lung cancer tumor xenografts were 
established subcutaneously (approximately 100 mm3 volume) in 
athymic mice and treated with a single oral dose of either NU5455 
(30 mg/kg) or the corresponding vehicle, 30 minutes before a 
single dose of tumor-localized irradiation. While a single dose 
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a single dose of NU5455 (30 mg/kg) ascertained by biolumines-
cent imaging (Figure 4A). NU5455 treatment enhanced the anti-
tumor effect of the radiation, with a significant difference in the 
time taken to achieve a 4-fold increase in bioluminescent signal 
(Figure 4B and Supplemental Figure 12A), and was well tolerated 
(Supplemental Figure 12B). The number of γH2AX foci evident 24 
hours after treatment was also increased significantly by NU5455 
in the orthotopically implanted lung tumors (Figure 4C). Since the 
nuclei of mouse lung epithelial cells are too small to accurately 
quantify γH2AX foci, the percentage of γH2AX-positive normal 
lung cells following 10 Gy of thoracic irradiation was determined 
instead. An examination of the corresponding lungs that did not 
Figure 3. NU5455 preferentially augments radiotherapy in subcutaneous Calu-6 and A549 lung tumor xenografts versus surrounding skin. (A) Mean 
tumor volume of mice bearing Calu-6 subcutaneous xenografts treated with NU5455 (30 mg/kg orally) or vehicle 30 minutes before localized radiation (0 
Gy or 3.3 Gy, 4–5 mice per group). (B and C) Number of γH2AX foci per nucleus in subcutaneous Calu-6 tumors (B) and the surrounding skin (C) collected 5 
and 24 hours after irradiation (3 mice per group). (D) NU5455 concentrations in the plasma, lung, skin, and subcutaneous Calu-6 tumors 15–360 minutes 
after oral administration of NU5455 (30 mg/kg, 3 mice per group). (E) Volume of subcutaneous Calu-6 tumors following treatment with NU5455 (30 mg/
kg orally) or vehicle 30 minutes after localized radiation (0 Gy or 10 Gy, 4–6 mice per group). (F) Corresponding percentage change in body weight of mice 
bearing Calu-6 tumors. (G) Number of 53BP1 and γH2AX foci per nucleus in Calu-6 tumors collected 24 hours after irradiation (3 mice per group). (H) Mean 
tumor volume from mice bearing A549 subcutaneous xenografts treated with NU5455 (30 mg/kg orally) or vehicle 30 minutes before localized radiation (0 
Gy or 10 Gy, 4–5 mice per group). (I) Number of 53BP1 and γH2AX foci per nucleus in A549 tumors collected 24 hours after irradiation (3 mice per group). All 
graphs represent the mean ± SEM. Statistical significance was assessed using unpaired t tests, with the exception of G and I, for which it was assessed by 
1-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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receive tumor implantation showed the number of γH2AX-posi-
tive cells to have been unaffected by NU5455 administration 24 
hours after irradiation (Figure 4D). In contrast, in SCID mice, 
which express a truncated, catalytically inactive form of DNA-PK 
as a result of a nonsense mutation in PRKDC (29), the percentage 
of γH2AX-positive normal lung epithelial cells following 10 Gy 
of thoracic radiation was approximately double that observed in 
CD-1 nude mice (Figure 4E), indicating that constitutive deletion 
of the target protein does have a significant effect on the response 
of a normal tissue to radiation.
Figure 4. NU5455 augments the effect of radiotherapy in orthotopically implanted Calu-6 lung tumors but does not enhance acute radiation damage 
to the lung. (A) Luciferase-expressing Calu-6 cells were injected into the left lungs of immunocompromised mice. One week after injection, mice were 
treated with NU5455 (30 mg/kg orally) or vehicle 30 minutes before thoracic radiation (0 Gy or 10 Gy, 3–4 mice per group). Tumor growth was monitored by 
bioluminescent imaging 0, 4, 8, and 15 days after treatment. (B) Representative bioluminescent images at days 0 and 15, with mean photon counts from 
the thoracic region of mice over time, and the time taken to reach 4 times the tumor luminescence at the start of treatment (RTL4). (C) Number of γH2AX 
foci per nucleus in orthotopic Calu-6 tumors collected 24 hours after irradiation (3 mice per group), with representative immunohistochemistry images. (D) 
Percentage of γH2AX-positive cells in normal lung tissue 24 hours after irradiation in mice treated with NU5455 (30 mg/kg orally) or vehicle 30 minutes 
before mock irradiation or 10 Gy treatment (3 mice per group), with representative images. (E) Percentage of γH2AX-positive cells in normal lung tissue 
from SCID mice 24 hours after receiving mock irradiation or 10 Gy treatment (3 mice per group). Scale bars: 25 μm. All graphs represent the mean ± SEM. 
Statistical significance was assessed using a log-rank test (B), 1-way ANOVA (C and D), and an unpaired t test (E). *P < 0.05, **P < 0.01.
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shown the combination of DNA-PK inhibitors with topoisomerase 
II inhibitors (which result in DNA-DSBs) to consistently lead to a 
large enhancement of cytotoxicity, ranging from 2- to 50-fold (14, 
31–33). Here we confirmed that NU5455 can enhance the cytotox-
icity of etoposide and doxorubicin, two widely used topoisomer-
ase inhibitors. NU5455 treatment (1 μM, 24 hours) resulted in a 
3.5-fold and 4.1-fold enhancement of doxorubicin- and etoposide- 
induced cytotoxicity (LD80) in Huh7 and SJSA-1 cells, respectively 
(Figure 6A). We found that NU5455 also induced a significant sen-
sitizing effect to doxorubicin in colorectal cancer (HCT116) and 
HCC (Hep3B and Huh7) cell lines with an LD80 sensitization rang-
ing from 3.1- to 5.1-fold, but with no effect in PRKDC–/– cells, which 
do not express DNA-PK (Figure 6B and Supplemental Figure 14).
We next sought to examine the effect of NU5455 treatment 
on parenteral etoposide treatment in the SJSA-1 tumor xenograft 
model. We examined oral dosing of NU5455 (30 mg/kg) or vehi-
cle immediately prior to etoposide administration (5 mg/kg i.p.) 
for 5 consecutive days in CD-1 nude mice bearing subcutaneous 
SJSA-1 tumors. Etoposide itself had a relatively marginal antitumor 
effect in vivo in this comparatively chemoresistant model, and the 
To examine the effect of NU5455 treatment on efficacy versus 
a late radiation toxicity, a total dose of 20 Gy of thoracic radiation 
was administered either to CD-1 nude mice bearing subcutane-
ous Calu-6 tumors or to non–tumor-bearing C57BL/6 mice, as 
four 5-Gy fractions given on days 1, 4, 7, and 10. This fractionat-
ed regimen was adapted from an existing method (30), resulting 
in focal areas of lung fibrosis at 24 weeks following treatment, 
but at a level that would enable any exacerbation of fibrosis to be 
readily detected. We also established that the plasma pharmaco-
kinetic profile of NU5455 was comparable in CD-1 nude mice and 
C57BL/6 mice (Supplemental Figure 13A). Administration of 2 
oral doses of 30 mg/kg NU5455 (30 minutes before and 5 hours 
after each radiation dose) was found to increase the time taken for 
human tumors in CD-1 nude mice to double in volume when com-
pared with those treated with radiation and vehicle (Figure 5A). In 
contrast, the same NU5455 treatment regimen did not exacerbate 
radiation-induced lung fibrosis in C57BL/6 mice (Figure 5B).
NU5455 sensitizes to topoisomerase II inhibitor treatment in vitro 
but has a narrow therapeutic index when combined with systemic 
chemotherapy in vivo. Our previous work and other studies have 
Figure 5. NU5455 augments the effect of fractionated radiotherapy in Calu-6 tumors without enhancing late radiation damage to the lung. (A) Mean 
tumor volume of mice bearing Calu-6 subcutaneous xenografts treated with localized radiation (4 × 5 Gy on days 1, 4, 7, and 10) with either NU5455 (30 
mg/kg orally) or vehicle 30 minutes before and 5 hours after each dose of IR (3–5 mice per group). The time taken to reach 2 times the tumor volume at 
the start of treatment (RTV2) was also assessed. (B) Masson’s trichrome staining was used to evaluate lung fibrosis in mice 24 weeks after treatment with 
thoracic radiation (4 × 5 Gy on days 1, 4, 7, and 10) with or without NU5455 (30 mg/kg orally) or vehicle 30 minutes before and 5 hours after each dose of IR. 
Samples were scored using the modified Ashcroft system on a scale of 0 to 8 (5–9 mice per group). Representative images are depicted. Scale bars: 100 μm 
(main images) and 4 mm (inset images). All graphs represent the mean ± SEM. Statistical significance was assessed using a log-rank test (A) and 1-way 
ANOVA (B). *P < 0.05, **P < 0.01, ****P < 0.0001.
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NU5455 can augment localized doxorubicin chemotherapy in 
HCC tumor xenografts without increasing toxicity. Following the 
observation that concomitant DNA-PK inhibition and systemic 
chemotherapy may have a narrow therapeutic index, we sought 
to examine oral NU5455 treatment in combination with localized 
chemotherapy, and selected doxorubicin-loaded DC M1 polymer 
beads (70–150 μm), which are used clinically in the treatment of 
HCC to deliver transarterial chemoembolization (34). In vitro, 
continuous incubation with either NU5455 (1 μM) or a single 
doxorubicin-loaded bead for 96 hours had a relatively small effect 
(~20% inhibition) on the density of Huh7 cells, which have high 
DNA-PK expression, whereas combination treatment reduced cell 
density by 57.7% ± 2.1% (Figure 7A). An analysis of γH2AX protein 
levels also suggested that NU5455 was able to augment and sus-
tain the DNA damage induced by released doxorubicin in Huh7 
dose of NU5455 used did not enhance it significantly (Supplemen-
tal Figure 15). We subsequently examined the effect of 100 mg/
kg of NU5455 given immediately prior to the administration of 
etoposide on 5 sequential days (Figure 6C), as this dose can main-
tain the plasma concentrations of NU5455 for a longer duration in 
mice (Supplemental Figure 13B). In this experiment, the antitumor 
activity of etoposide was indeed potentiated significantly; howev-
er, it was accompanied by increased weight loss by day 8 (Figure 
6D) with a requirement to intervene and humanely euthanize 2 ani-
mals because of a sudden deterioration in clinical condition (>15% 
body-weight loss). These data suggest that it is possible to augment 
the activity of parenteral etoposide with concomitant DNA-PKcs 
inhibition, but that this requires a greater dose of NU5455, which, 
although well tolerated by itself, is associated with greater toxicity 
in combination and denotes a limited therapeutic gain.
Figure 6. NU5455 sensitizes tumors to topoisomerase II inhibitors but has a narrow therapeutic index when combined with systemic chemotherapy in 
vivo. (A) Clonogenic survival of Huh7 and SJSA-1 cells pretreated with vehicle or NU5455 (1 μM) for 1 hour before the addition of doxorubicin or etoposide 
for 24 hours before replating into drug-free media. (B) LD80 values from clonogenic survival assays of human tumor cell lines pretreated with vehicle or 
NU5455 (1 μM) for 1 hour before the addition of doxorubicin or etoposide for 24 hours before reseeding into drug-free media. Fold potentiation is indicated 
for each cell line. A and B depict the mean ± SEM from 3 independent experiments. (C) Mice bearing subcutaneous SJSA-1 tumor xenografts (103–121 mm3) 
were treated with NU5455 (100 mg/kg orally) with or without etoposide (5 mg/kg, i.p.) daily for 5 days. (D) Mean SJSA-1 tumor volume, and percentage 
body weight at day 8 relative to pretreatment body weight on day 1 (5–10 mice per group). †Humane intervention was required at day 8 for 2 of 10 mice 
receiving combination treatment. All graphs represent the mean ± SEM. Statistical significance was assessed using unpaired t tests (A and B) and 1-way 
ANOVA (D). *P < 0.05, **P < 0.01, ***P < 0.001.
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tion of NU5455 (30 mg/kg, b.i.d.) to mice bearing subcutaneous 
HCC xenografts into which doxorubicin-eluting beads had been 
implanted intratumorally (Figure 7C). An enhanced antitumor 
effect was observed with combination treatment versus either 
monotherapy (Figure 7D; mean RTV4 value of 17.8 days for the 
cells for at least 96 hours (Figure 7B). Importantly, NU5455 did not 
directly influence the rate of doxorubicin elution from the beads 
(Supplemental Figure 16).
Chronic treatment with NU5455 in vivo was then examined 
in conjunction with localized chemotherapy, by oral administra-
Figure 7. NU5455 augments localized doxorubicin chemotherapy in HCC tumor xenografts without increased toxicity. Exponentially growing Huh7 cells in 
6-well plates were treated with NU5455 (1 μM) or DMSO for 1 hour before the addition of a single doxorubicin-loaded 70- to 150-μm DC M1 bead (25 mg/mL) 
to the center of each well. (A and B) Cell density was determined after 96 hours of continuous treatment using sulforhodamine B staining (A), and protein 
extracts were taken for the detection of γH2AX via Western blotting after 24–96 hours of continuous treatment (n = 3) (B). (C) Mice bearing established Huh7 
subcutaneous xenografts (180–220 mm3) were treated with 5 μL DC M1 beads loaded with 25 mg/mL doxorubicin, or unloaded beads. Beads were suspended 
in 30 μL saline and implanted via an intratumoral injection. Twice-daily dosing with NU5455 (30 mg/kg orally, 9-hour dosing interval) or vehicle control was 
commenced 60 minutes after bead implantation. (D) Mean Huh7 tumor volume over time (6 mice per group). (E) Percentage body weight at day 8 relative to 
pretreatment body weight on day 1. (F) Percentage phospho–DNA-PKcs Ser2056 nuclear positivity in Huh7 tumor sections, and high (grade III) γH2AX nuclear 
positivity in a 400-μm radius surrounding individually embedded beads (5 mice per group). Representative images of phospho–DNA-PKcs Ser2056 and 
γH2AX staining in Huh7 tumor xenografts treated with unloaded or doxorubicin-loaded DC M1 beads. Scale bars: 200 μm. All graphs represent the mean ± 
SEM. Statistical significance was assessed using 1-way ANOVA (A, E, and F) and unpaired t test (D). **P < 0.01, ***P < 0.001, ****P < 0.0001.
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ther studies to elucidate potential determinants of tumor cell sen-
sitivity are warranted. Such work may assist in the development of 
biomarker strategies to aid the selection of patients with increased 
sensitivity to combination treatment.
Our data with NU5455 indicates that there is the potential to 
realize a differential potentiation of radiation-induced DNA dam-
age in tumor versus normal tissues by transient DNA-PKcs inhibition 
in vivo. This is based on measurements of tumor growth response, 
acute DNA damage in tumor versus skin or lung, and the lack of an 
effect of NU5455 treatment on a late normal tissue toxicity (lung 
fibrosis). Consistent with this, a recent preclinical study examining 
VX-984 has shown it to increase the efficacy of cranial irradiation 
against an orthotopically implanted human glioblastoma tumor 
without an apparent effect on clinical condition (38). Although 
rodent tissues are known to express less DNA-PK than those of 
human origin (39), it is unlikely that the differential radiosensitizing 
effect of NU5455 treatment in human tumors versus normal mouse 
tissues is attributable to a difference in the murine DNA damage 
response, given that SCID mice exhibit enhanced skin radiosensi-
tivity (40), and lung fibroblasts from mice with homozygous dele-
tion of the gene encoding DNA-PK (41) or normal murine fibroblasts 
treated with a DNA-PKcs inhibitor (42) are significantly sensitized 
to radiation treatment. Furthermore, NU5455 enhanced the cell 
killing effect of radiation in murine nontumor and tumor cell lines in 
vitro to a level that was comparable to that observed in most human 
cell lines. In addition to there being potential cell-intrinsic determi-
nants that may more favorably influence the radio-enhancement of 
some tumors after DNA-PKcs inhibition, the therapeutic index aris-
ing from this pharmacological strategy may be influenced by both 
the magnitude and the duration of DNA-PKcs inhibition. Certainly, 
the intrinsic sensitivity of SCID mouse lung to radiation was signifi-
cantly greater than that of a CD-1 nude mouse lung with NU5455 
treatment, suggesting that complete genetic deletion of DNA-PK 
does not phenocopy transient pharmacological inhibition of DNA-
PKcs. Our in vitro data also show the radio-enhancing effect of 
NU5455 in tumor cells to be highly dependent on the duration of 
compound incubation following irradiation, which is likely to reflect 
a time-dependent repair of sublethal damage with extended treat-
ment resulting in the persistence of γH2AX foci. Given that micro-
molar levels of NU5455 are evident in plasma and tissue for only 
3–4 hours in vivo following oral administration of 30 mg/kg, the 
pharmacokinetics of this compound may conceivably contribute to 
the observed therapeutic gain. The use of episodic DNA-PK inhibi-
tion, as opposed to continuous or sustained inhibition, may also be 
beneficial in extended combination regimens, since it may avoid a 
potential effect on telomere maintenance, which has been shown 
to have DNA-PK dependency in human cells (43). It remains to be 
determined whether the duration of DNA-PKcs inhibition can result 
in the differential radio-enhancement of tumors versus normal tis-
sues, but this is also worthy of further examination, and it will be of 
interest to compare DNA-PK inhibitors with different pharmacoki-
netic profiles. Indeed, PARP inhibitors have been previously found 
to augment the toxicity of radiotherapy to the skin and esophagus of 
mice, which may be influenced by their pharmacokinetic profile or 
a prolonged pharmacodynamic effect (44, 45).
Our in vitro experiments also indicate that combined IR and 
NU5455 treatment can have a significantly greater cell-killing 
combination vs. either 10.6 days for NU5455 with unloaded beads 
or 11.1 days for doxorubicin beads with vehicle, P < 0.01 by 2-tailed 
Mann-Whitney U test), and no additional impact on body weight 
(Figure 7E and Supplemental Figure 17A) or clinical condition 
was observed versus treatment with vehicle alone. Immunohisto-
chemical analysis after 72 hours of treatment revealed that DNA-
PKcs phosphorylation (Ser2056) was elevated in mice treated with 
doxorubicin-loaded beads, and that this was reduced by NU5455 
treatment (Figure 7F). DNA damage (γH2AX) in Huh7 tumors, in 
the area surrounding doxorubicin-eluting beads, was also signifi-
cantly augmented by NU5455 treatment at 72 hours. Represen-
tative images of stained tumor sections analyzed using a nuclear 
positivity algorithm are shown (Supplemental Figure 17, B and 
C). These data indicate that oral administration of NU5455 can 
enhance the effect of doxorubicin-eluting beads in tumors, with-
out inducing any adverse effects.
Discussion
Herein we describe the discovery of NU5455, a highly selective 
orally bioavailable inhibitor of DNA-PKcs. While there has been 
significant interest in inhibiting DNA-PKcs for therapeutic bene-
fit, we are not aware of any preclinical studies that have critically 
evaluated both the normal and tumor tissue response to concom-
itant treatment with a selective DNA-PKcs inhibitor and therapies 
that induce DNA-DSBs. That inhibition of DNA-PKcs kinase activ-
ity can induce radiosensitization of tumor cells has been previous-
ly established genetically and pharmacologically (32, 35), and the 
ability of NU5455 to impart a greater radio-enhancement than 
small-molecule inhibitors of the DNA repair proteins ATM, PARP, 
and ATR is consistent with DNA-PK having a critical role in the 
repair of DNA-DSBs that represent the most lethal DNA damage 
lesion (1). NU5455 enhanced the effect of IR in vitro across a range 
of human tumor cell lines, including those that are representative 
of tumor types commonly treated clinically with external beam 
radiotherapy (glioblastoma, osteosarcoma, lung and colorectal 
cancer). However, the magnitude of radio-enhancement observed 
across the cell panel was unrelated to the intrinsic radiosensitivity 
of the cell lines or their basal DNA-PK expression (Supplemen-
tal Figure 18). This variance in radio-enhancement may relate 
to a variety of innate cellular differences such as the capacity to 
overcome oxidative stress, the propensity to resist apoptosis, or, 
as suggested recently following studies with the DNA-PK inhibitor 
VX-984 (36), the ability to use compensatory DNA repair mecha-
nisms. It has also been suggested that greater radio-enhancement 
can be observed in tumor cells following DNA-PKcs inhibition 
on the basis of p53 status, the loss of functional p53 leading to 
enhanced cell death through mitotic catastrophe and the induc-
tion of apoptosis (37). However, loss of functional p53 through 
either mutation or deletion (evident in SN40R2, Calu-6, Huh7, 
Hep3B, U251, 4T1, and HCT116 TP53–/– cells; Supplemental Table 
3) did not explain any differences in radio-enhancement observed 
with NU5455 in our cell line panel (Figure 2F). Furthermore, 
we did not find evidence of an enhanced apoptotic response in 
isogenic HCT116 colorectal tumor cells that lacked TP53 following 
treatment with NU5455 and radiation (Supplemental Figure 19). 
Given that pleiotropic mechanisms may influence the response to 
combined radiotherapy and DNA-PKcs inhibitor treatment, fur-
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2010/136778 (example 102; compound 143). NU5455 was dissolved 
in DMSO for in vitro work, and prepared in N-methyl-2-pyrrolidone 
(NMP)/30% encapsin/PEG400 (1:6:3 vol/vol/vol) or 1% acetic acid 
(vol/vol) for oral administration in vivo. NU7441 was synthesized as 
detailed by Leahy et al. (51). KU55933, rucaparib, and VE-821 were pur-
chased from Tocris Bioscience. All other reagents were purchased from 
Sigma-Aldrich unless otherwise stated. All compounds were dissolved 
in anhydrous DMSO and stored in small aliquots at –20°C, unless oth-
erwise stated. Doxorubicin solutions were prepared in sterile, molecu-
lar-grade water and stored under light-protected conditions at 4°C.
In vitro kinase selectivity screening. The in vitro kinase selectivity 
of NU5455 was determined using the SelectScreen Broad Assay Panel 
(Thermo Fisher Scientific) involving activity and binding assays (Sup-
plemental Table 1). The ATP concentration used in activity assays was 
the Km[app] where available, or 10 or 100 μM as indicated (Supple-
mental Table 1). Class IA PI3Ks were measured using the p85α subunit.
Cellular activity of NU5455 against DNA-PK and PI3K. Exponen-
tially growing MCF7 cells were exposed to a range of concentrations 
of NU5455 and NU7441 (0.03–10 μM) for 1 hour. To assess the ability 
of NU5455 and NU7441 to inhibit autophosphorylation of DNA-PKcs 
at Ser2056, cells were treated with 10 Gy irradiation and incubated for 
30 minutes. Alternatively, to investigate the effects of NU5455 and 
NU7441 against PI3K-dependent phosphorylation of AKT at Ser473, 
cells were treated with 50 ng/mL insulin-like growth factor-1 (IGF-1; 
Invitrogen) for 30 minutes. Cell lysates were prepared for the detec-
tion of p–DNA-PKcs Ser2056 and total DNA-PKcs, or p–AKT Ser473 
and total AKT, respectively, using Western blotting.
NHEJ plasmid repair assay. The ability of NU5455 to impair the 
nonhomologous end joining (NHEJ) ability of cells was assessed using 
a modified version of a DNA repair assay developed by Nagel et al. (52), 
which measures the repair of a plasmid encoding blue fluorescent pro-
tein (BFP) and GFP linearized by either an ScaI or an AfeI restriction 
digestion. Full experimental details are given in Supplemental Methods.
In vivo experiments. Mice were purchased at 6–10 weeks of age from 
Charles River UK Ltd. NU5455 was dosed orally at 0.1 mL/10 g body 
weight using the NMP/30% encapsin/PEG400 formulation for all exper-
imental work with the exception of the HCC xenograft study, in which the 
1% (vol/vol) acetic acid formulation was used (Figure 7). All tumor xeno-
graft experiments were conducted in CD-1 nude mice with the exception 
of the Calu-6 subcutaneous xenograft combination studies (Figure 3), 
which were performed in BALB/c nude mice. Lung fibrosis experiments 
were performed in C57BL/6 mice. Comparable NU5455 plasma pharma-
cokinetic data were obtained following 30 mg/kg oral dosing of NU5455 
to each mouse strain examined (Supplemental Figure 13).
Combining NU5455 and targeted radiotherapy in subcutaneous lung 
tumor xenografts. Subcutaneous non–small cell lung cancer xenografts 
were generated in CD-1 nude or BALB/c nude mice using A549 and 
Calu-6 cells, respectively, as previously described (53). When tumors 
reached 100 mm3, mice were randomized into 4 groups (n = 7–9 per 
group) to receive (a) vehicle (orally) 30 minutes before mock radiation, 
(b) NU5455 (30 mg/kg orally) 30 minutes before mock radiation, (c) 
targeted tumor radiation at a single dose of 3.3 or 10 Gy, or (d) NU5455 
(30 mg/kg orally) 30 minutes before 3.3 Gy or 10 Gy targeted tumor 
radiation. For targeted irradiation of subcutaneous tumors, anesthe-
tized mice were restrained in a lead-shielded container with only the 
tumor exposed, and x-ray radiation applied using an RS320 irradiation 
system (Gulmay Medical) at a dose rate of 1.82 Gy/min.
effect in proliferating, as opposed to confluent, MCF7 tumor cells. 
This observation could conceivably provide the basis for a differen-
tial sensitivity to IR and NU5455 treatment in proliferating tumor 
cells versus comparatively quiescent normal tissue. Data generated 
in MCF10A cells, however, suggest that the impact of cellular pro-
liferation rate on the response to combination treatment can vary 
between different cell types, potentially reflecting divergences in 
how different cells process, repair, and respond to DNA-DSBs in 
the presence of DNA-PK inhibition, which will also be of interest 
to evaluate further. Alternatively, other facets of tumor pathophys-
iology, such as tumor hypoxia, may favorably influence the radio- 
response in vivo, with DNA-PKcs inhibition potentially having a 
preferential radiosensitizing effect in hypoxic tumor cells (46), 
which would otherwise represent a more radioresistant population.
When combined with a parenterally administered topoisom-
erase II inhibitor, NU5455 did show evidence of increased tox-
icity, suggesting that concomitant use of a DNA-PKcs inhibitor 
with systemic DNA-DSB therapies is likely to be challenging to 
implement clinically. Topoisomerase II inhibitors induce DNA 
damage via catalysis of DNA-DSBs during replication and tran-
scription, which is a more gradual response when compared with 
the acute DNA-damage effects of IR. Optimal enhancement of 
such a response is likely to require more extended DNA-PKcs inhi-
bition, perhaps requiring multiple daily dosing or longer half-life 
compounds, but which may also exacerbate the more widespread 
insult of the chemotherapy on a range of normal tissues. The con-
cept of combining a DNA-PKcs inhibitor with localized chemo-
therapy is therefore highly attractive, exemplified by our data that 
show the efficacy of intratumoral doxorubicin-eluting beads in 
mice to be enhanced significantly by oral NU5455 administration, 
without evidence of overt toxicity. This strategy is of potential 
clinical relevance to the treatment of HCC, in which transarterial 
chemoembolization (TACE) procedures with doxorubicin-con-
taining beads are used (47) — a disease that has a particularly high 
mortality and in which new therapeutic interventions have had 
limited impact (48). Such use may require concomitant adminis-
tration of a DNA-PK inhibitor for a period of 2–4 weeks, during the 
period in which doxorubicin is eluted from the beads (49). Since 
high DNA-PK expression and activation in HCC has been found to 
correlate with resistance to TACE (14), an HCC patient selection 
strategy for early clinical evaluation of a DNA-PKcs inhibitor could 
involve an examination of tumor DNA-PK in a diagnostic biopsy or 
in circulating tumor cells (50), with those showing highest activity 
being chosen for combination treatment.
In conclusion, the identification of NU5455 and the preclini-
cal data generated in cancer models suggest that it is possible to 
achieve an enhanced therapeutic ratio with transient selective 
pharmacological inhibition of DNA-PKcs in combination with 
DNA-DSB–inducing therapies. The application of a DNA-PKcs 
inhibitor, as an adjunct either to radiotherapy or to current HCC 
treatment, creates exciting therapeutic opportunities that necessi-
tate further evaluation toward clinical implementation.
Methods
Reagents. NU5455 and NU7441 were synthesized by the Newcastle 
University Medicinal Chemistry Department or NewChem Technolo-
gies Ltd. Full synthesis details for NU5455 are provided in patent WO 
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reach 2 times the tumor volume at the start of treatment (RTV2) were 
examined using Kaplan-Meier analyses. P values less than 0.05 were 
considered to indicate statistical significance and are denoted in the 
figures as follows: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001. NS indicates not significant, P > 0.05.
All other methods are detailed in Supplemental Methods. For 
inquiries concerning the synthesis of NU5455, contact CC, celine.
cano@ncl.ac.uk.
Study approval. All experiments with mice were approved by 
the Animal Welfare Ethical Review Boards at Newcastle University 
(Newcastle upon Tyne, UK) and the University of Oxford (Oxford, 
UK), in accordance with published guidelines (56) and the UK Ani-
mals (Scientific Procedures) Act, 1986, under PPL numbers 70/8769, 
60/4222 and 30/3395.
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Combining NU5455 and targeted radiotherapy in orthotopic lung 
tumor xenografts. Orthotopic lung xenografts were generated follow-
ing a published protocol (54) with minor modifications. Briefly, CD-1 
nude mice (Charles River Laboratories) were anesthetized with 2% 
isoflurane and placed in the right lateral decubitus position. Lucifer-
ase-expressing Calu-6 cells (1 × 106) in 50 μL of 50% (vol/vol) Matri-
gel were injected into the left lateral thorax at the lateral dorsal axillary 
line, 1.5 cm above the lower rib line. The needle was advanced 5 mm 
into the thorax. After injection, the mouse was turned to the left later-
al decubitus position for 5 minutes. Fourteen days after implantation, 
mice were treated with vehicle, NU5455 (30 mg/kg orally), whole- 
thorax irradiation (10 Gy), or NU5455 combined with 10 Gy thorax 
irradiation (n = 6–7 per group). For whole-thorax radiation, anesthe-
tized mice were restrained in a lead-shielded container with only the 
thoracic region exposed. X-ray radiation was applied using an RS320 
irradiation system at 2.034 Gy/min (Gulmay Medical). Additional 
details are presented in Supplemental Methods.
Combining NU5455 and localized doxorubicin-eluting bead therapy 
in HCC tumor xenografts. DC M1 beads were loaded with doxorubicin 
at 25 mg/mL as described in Supplemental Methods. Huh7 cells (5 × 
106 cells per mouse in 50 μL, 50% vol/vol Matrigel) were implanted 
s.c. into the right flank of female CD-1 nude mice to generate subcu-
taneous Huh7 xenografts (180–220 mm3). Mice were then treated 
with 5 μL doxorubicin-loaded or unloaded beads suspended in 30 μL 
saline administered via an intratumoral injection along the length of 
each tumor using a 29G needle. One hour after bead implantation, 
twice-daily dosing with 30 mg/kg NU5455 or vehicle control (1% vol/
vol acetic acid in water) was commenced via oral gavage (9-hour dos-
ing interval) and continued for up to 20 days. Tumor volumes were 
calculated daily using bilateral caliper measurements as described in 
Supplemental Methods, and body weight measurements taken daily 
throughout treatment.
Lung fibrosis studies. Whole-thorax irradiation (5 Gy) was adminis-
tered to female C57BL/6 mice (6–8 weeks old) on days 1, 4, 7, and 10 
with vehicle or NU5455 treatment. Whole lung sections were stained 
with Masson’s trichrome to visualize collagen deposition and scored 
using the modified Ashcroft scale proposed by Hübner et al. (55). Fur-
ther details are provided in Supplemental Methods.
Statistics. Data were analyzed using GraphPad Prism 6.0 software 
(GraphPad Inc.). Two-tailed, unpaired t tests were used to assess sta-
tistical significance between 2 treatment groups, unless otherwise 
specified. ANOVA tests with Bonferroni’s correction for multiple 
comparisons were used to examine differences between up to 5 treat-
ment groups. Differences in the time taken to reach 4 times the tumor 
luminescence at the start of treatment (RTL4), and the time taken to 
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